Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
Larazotide is a peptide that may reduce gut permeability by strengthening your gut lining (11)
A few special warnings are worth noting
The concentration may not match the label
How BPC-157 Works in the Body Once in your system, either through an injection or an oral supplement, BPC-157 supports the body at a cellular level, promoting healing and improving blood flow to damaged areas
US$ 23.14
US$ 29.01
US$ 27.85
US$ 20.87
US$ 27.84
US$ 26.04
US$ 22.66
US$ 25.30
US$ 28.98
